Decode Genetics news from FierceBiotech

Iceland's deCODE genetics says that its heart attack prevention drug--DG051--produced convincingly positive data in a Phase IIa study, paving the way to a Phase IIb. This recent study produced data Read more...

Press Release: Positive Clinical Results for DG041

Read more...

DeCode Genetics announced today that a mid-stage study of its arterial thrombosis treatment showed positive results in a Phase II study. The company says it expects DG041 will make it possible to block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. With the development of DG041, DeCode is taking aim at drugs such as Plavix and aspirin, the current market leaders of oral anti-platelet therapy.

- see …

Read more...

> The generic drug maker Dr. Reddy's Laboratories plans to raise $260 million through an issue of 13.5 million American Depositary Shares. The Indian company has been on an acquisition spree, acquiring Germany's Betapharm in March as it pursued a strategy of expanding in the European market. Report

> The …

Read more...

Iceland's deCode Genetics has suspended a late-stage trial of the heart attack prevention drug veliflapon after determining that the tablets being used weren't dissolving properly. Researchers were concerned that the faulty tablets would have skewed the data on the drug. The developer announced that it had notified the FDA and was looking at alternative manufacturing sources to resolve the issue. Veliflapon is directed …

Read more...

Iceland's deCODE Genetics is suing five former employees for allegedly stealing research knowledge and trade secrets and using them at Children's Hospital in Philadelphia. And the biotech company says the theft was done with the knowledge of the hospital staff, an allegation the hospital denies. Hakon Hakonarson, deCODE's former vice president of business development, is named in the suit along with four others recruited by the Center for Applied Genomics, which is part of Children's …

Read more...

> Raven biotechnologies had reported positive early results of a Phase I clinical trial of RAV12, its lead therapeutic antibody in development for the treatment of adenocarcinomas. Release

> In Mexico and Guatemala, the Iomai Corporation has begun enrollment in a Phase II trial to test its vaccine patch for travelers' diarrhea. …

Read more...

> Bradley Sheares, the head of Merck's U.S. drug operations, has left the company. Sheares was once considered a contender for the CEO's job. Adam Schechter is being promoted to replace him. Report

> Siga Technologies announced that its lead smallpox candidate, SIGA-246, successfully demonstrated that it was safe and …

Read more...

Iceland's DeCode Genetics has launched a closely watched Phase III trial of DG031 to prevent heart attacks. The company will track the results of 3,400 African-American subjects who have a genetic variant linked to heart attacks. Report

> Canada's Medicure plans to raise $25 million in a private placement to fund clinical development of its two lead products. Release

> DeCode genetics has reached an agreement with the FDA on the design of a Phase III trial of DG031 to prevent heart attacks. Report

> …

Read more...